



Supplementary Fig. 1: Measure of anti-SARS-CoV-2 Ab in COVID-19 convalescent human plasma. (a) SARS-CoV-2 IgG determination in plasma from COVID-19 convalescent subject by automated commercial iFlash method (Shenzhen YHLO, PRC) was performed by provider (Biomex GmbH Heidelberg, Germany) and expressed in Arbitrary Unit (AU)/mL. Dot line represent the cut-off of 10 AU/mL. The panel of 20 samples was separated in two groups of 10 samples based on Ab binding titers either Low (<47AU/mL) or High (>47AU/mL). (b) The same 2 High and Low groups were tested for specific binding to recombinant SARS-CoV-2 S(S1+S2) in ELISA as described in Material and Methods. Four COVID-19 negative human plasma samples (C-) collected before emergence of SARS-CoV-2 were also tested in the same experiment. Results are expressed in end point titer (EPT) reciprocal dilution. Red dot represents a sample for which commercial assay and in-house ELISA gave marked discrepancy. (c) Neutralizing activity was measured by PRNT90 as described in Material and Methods in pools of Low and High groups.